Jingfang Pharmaceutical-B announced that the updated data of the company's GFH375 phase II trial for treating KRAS G12D mutant non-small cell lung cancer was published in the oral report at the 2026 World Lung Cancer Conference on September 14. As of the data cutoff date, 71 patients were assessed after at least one treatment, with an objective response rate of 59.2%, a confirmed objective remission rate of 52.1%, and a disease control rate of 93%.

Jingfang Pharmaceutical-B announced that the updated data of the company's GFH375 phase II trial for treating KRAS G12D mutant non-small cell lung cancer was published in the oral report at the 2026 World Lung Cancer Conference on September 14. As of the data cutoff date, 71 patients were assessed after at least one treatment, with an objective response rate of 59.2%, a confirmed objective remission rate of 52.1%, and a disease control rate of 93%.